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ABSTRACT Immune control of viral infections is heavily dependent on helper CD4
T cell function. However, the understanding of the contribution of HIV-speciﬁc CD4
T cell responses to immune protection against HIV-1, particularly in clade C infec-
tion, remains incomplete. Recently, major histocompatibility complex (MHC) class II
tetramers have emerged as a powerful tool for interrogating antigen-speciﬁc CD4 T
cells without relying on effector functions. Here, we deﬁned the MHC class II alleles
for immunodominant Gag CD4 T cell epitopes in clade C virus infection, con-
structed MHC class II tetramers, and then used these to deﬁne the magnitude, func-
tion, and relation to the viral load of HIV-speciﬁc CD4 T cell responses in a cohort
of untreated HIV clade C-infected persons. We observed signiﬁcantly higher frequen-
cies of MHC class II tetramer-positive CD4 T cells in HIV controllers than progres-
sors (P  0.0001), and these expanded Gag-speciﬁc CD4 T cells in HIV controllers
showed higher levels of expression of the cytolytic proteins granzymes A and B. Im-
portantly, targeting of the immunodominant Gag41 peptide in the context of HLA
class II DRB1*1101 was associated with HIV control (r  0.5, P  0.02). These data
identify an association between HIV-speciﬁc CD4 T cell targeting of immunodomi-
nant Gag epitopes and immune control, particularly the contribution of a single
class II MHC-peptide complex to the immune response against HIV-1 infection. Fur-
thermore, these results highlight the advantage of the use of class II tetramers in
evaluating HIV-speciﬁc CD4 T cell responses in natural infections.
IMPORTANCE Increasing evidence suggests that virus-speciﬁc CD4 T cells contrib-
ute to the immune-mediated control of clade B HIV-1 infection, yet there remains a
relative paucity of data regarding the role of HIV-speciﬁc CD4 T cells in shaping
adaptive immune responses in individuals infected with clade C, which is responsi-
ble for the majority of HIV infections worldwide. Understanding the contribution of
HIV-speciﬁc CD4 T cell responses in clade C infection is particularly important
for developing vaccines that would be efﬁcacious in sub-Saharan Africa, where
clade C infection is dominant. Here, we employed MHC class II tetramers de-
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signed to immunodominant Gag epitopes and used them to characterize CD4 T
cell responses in HIV-1 clade C infection. Our results demonstrate an association
between the frequency of HIV-speciﬁc CD4 T cell responses targeting an immu-
nodominant DRB1*11-Gag41 complex and HIV control, highlighting the impor-
tant contribution of a single class II MHC-peptide complex to the immune re-
sponse against HIV-1 infections.
KEYWORDS CD4 T helper cells, MHC class II tetramers, human immunodeﬁciency
virus, HIV
Detailed characterization of immune cells that contribute to the suppression of HIVreplication is critical to both vaccine design and therapeutic approaches. Although
both CD4 and CD8 T cells mediate cellular immune responses to HIV, most research
efforts have focused on understanding the role of CD8 T cells. In contrast, the role of
CD4 T cells is less well deﬁned. CD4 T cells contribute to the immune control of
many viral infections (1–6), implying that they may be similarly important for HIV
immunity. Indeed, recent studies in individuals with HIV clade B infection have high-
lighted the important role of HIV-speciﬁc CD4 T cells as effectors of viral immunity (7,
8), in addition to being orchestrators of CD8 T cell and B cell responses via helper
signals (9).
Although CD4 T cell responses remain relatively understudied, emerging evidence
suggests that they play a more active role in controlling HIV disease progression than
was previously thought. A recent study of simian immunodeﬁciency virus provided the
ﬁrst direct evidence of a CD4 T cell-driven escape mutation (10). In that study, the
investigators identiﬁed a unique postbreakthrough mutation in the Gag region tar-
geted only by CD4 responses, which abrogated CD4 T cell recognition (10). In humans,
indirect evidence generated by a computational approach identiﬁed HLA class II-
associated polymorphisms and linked predicted epitopes within adaptation sites to
CD4 T cell-driven immune escape (11). Furthermore, recent studies conducted in
predominantly Caucasian populations with clade B HIV infection showed that targeting
of Gag by CD4 T cell responses restricted by some HLA-DRB1 alleles, such as
DRB1*15:02, 13:01 and DQB*:06, was associated with low levels of viremia, whereas the
CD4 responses restricted by the DRB1*03:01 allele were linked to high levels of viremia.
The plausible explanation for the difference was that DRB1 alleles associated with low
viremia had the capacity to present multiple epitopes at low functional avidity com-
pared to alleles associated with high viremia, where a signiﬁcantly lower number of
promiscuous peptide restrictions are observed (12–14). Taken together, these data
underscore the impact of HIV-speciﬁc CD4 T cell responses on the control of HIV
replication.
In contrast to these studies in individuals with clade B virus infection, much less is
known about the role of CD4 T cell responses in individuals with clade C HIV infection.
An improved understanding of the immune responses to clade C is particularly impor-
tant for the development of vaccines that would be efﬁcacious in sub-Saharan Africa,
where subtype C viruses, which account for more than 50% of infections globally, are
most dominant (15). A few studies of clade C have identiﬁed immunodominant class
II-restricted CD4 T cell epitopes, but the restricting alleles for these responses remain
unknown (16, 17). The lack of knowledge about the restricting alleles has made it
difﬁcult to synthesize class II tetramers that could be used to conduct more compre-
hensive CD4 T cell studies without relying on speciﬁc effector functions. Most clade
C studies have used gamma interferon (IFN-) intracellular cytokine staining (ICS) or
enzyme-linked immunosorbent spot (ELISPOT) assays to study CD4 T cell responses
(17). This approach is limited in scope because it can detect the responses only of
IFN--secreting CD4 T cells and is therefore more likely to miss other CD4 T cell
subsets that are deﬁned by different signature cytokines, such as Th-2, Th-17, and T
follicular helper cells and regulatory T cells.
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To investigate if virus-speciﬁc CD4 T cells play an active antiviral role in the
pathogenesis of clade C HIV infection, we ﬁrst screened the entire HIV-1 clade C
proteome for immunodominant HIV-speciﬁc CD4 T cell epitopes and performed class
II restriction studies to identify the most frequent class II DRB1 alleles in an initially
untreated study population predominantly of Zulu/Xhosa ethnicity in a region where
clade C is endemic. The screening data were used to synthesize major histocompati-
bility complex (MHC) class II tetramers to the most immunodominant CD4 T cell
epitopes. The tetramers were then used to thoroughly examine the frequency and
function of HIV-speciﬁc CD4 T cell responses during chronic untreated HIV-1 clade C
infection. Our data demonstrate that the frequency of immunodominant Gag-speciﬁc
CD4 T cells measured by the tetramers is inversely associated with the contempora-
neous viral load. These data highlight the important contribution of HLA class II-
restricted epitope-speciﬁc CD4 T cells to the immune response against HIV-1 clade C
infection and indicate that MHC class II tetramers are a sensitive tool for interrogating
HIV-speciﬁc CD4 T cell responses in natural infections.
RESULTS
To better understand the role of HIV-speciﬁc CD4 T cell responses in HIV control
and disease progression, we comprehensively investigated the speciﬁcity and func-
tional properties of these responses in the setting of chronic clade C HIV-1 infection
using IFN- ELISPOT assays and multiparameter ﬂow cytometry with MHC class II
tetramers. Modiﬁed IFN- ELISPOT assays were used to identify immunodominant
HIV-speciﬁc CD4 T cell epitopes and restricting alleles in our cohort with chronic
infection to inform the production of appropriate MHC class II tetramers. MHC class II
tetramers were then utilized to detect low-frequency populations of antigen-speciﬁc
CD4 T cells (which may be missed in conventional peptide stimulus-based assays).
This approach enabled the direct ex vivo characterization of antigen-speciﬁc HIV-
speciﬁc CD4 T cell responses targeting immunodominant Gag epitopes.
Immunodominance hierarchy of CD4 T cell responses in chronic clade C
infection. Here, we evaluated a cohort of 72 untreated individuals chronically infected
with HIV clade C. HIV-speciﬁc CD4 T cell responses against a panel of 410 pooled
peptides spanning the entire HIV-1 clade C consensus sequence were initially screened
using the IFN- ELISPOT megamatrix assay. Results from the initial megamatrix assay
screening were validated using conﬁrmatory IFN- ELISPOT assays at the single-peptide
level. Our data demonstrate that HIV-speciﬁc CD4 T cell responses in chronic clade C
infection dominantly target the Gag protein (Fig. 1A). The most commonly targeted
region in Gag was the p24 subprotein (20/63 peptides), while the p17 and p15 regions
of Gag were subdominantly targeted by CD4 T cells (12/63 peptides each). The p24
region of Gag has also been shown to be immunodominant for HIV-speciﬁc CD8 T cell
responses, and these responses have previously been associated with viral control (18).
However, no correlation between the breadth of Gag-speciﬁc CD4 T cell responses
(Spearman r0.17, P 0.42) as well as the magnitude of these responses (Spearman
r 0.22, P 0.30), as measured by ELISPOT assays, and the contemporaneous viral load
was observed. At the epitope level, our data showed that Gag peptide 41 (Gag41)
within the p24 subunit is the most immunodominant peptide, with over 40% of the
subjects in our cohort showing a detectable response to this peptide (Table 1). A
previous study found Gag6 in p17 to be the most dominant epitope (17). The difference
may be due to the different proportions of controllers and progressors between the
two studies.
The second most commonly targeted epitope was Gag40 (23%). Interestingly, only
two responders targeted both the adjacent peptides, indicating the presence of distinct
epitopes rather than targeting of the shared overlap represented in each peptide. Gag6,
Gag25, and Gag37 were targeted independently by 20% of the 30 responders (Table 1).
Additional immunodominant epitopes were located within the Nef region of the
proteome (7/63 peptides). The results highlight a large number of detectable HIV-
speciﬁc CD4 T cell responses across the HIV proteome dominantly targeting Gag and
MHC Class II Tetramers and CD4 T Cell Responses Journal of Virology
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Nef, ﬁndings consistent with those of previous studies (17). We observed that Gag-
speciﬁc CD4 T cell responses are immunodominant and are directed at multiple
distinct epitopes, with very few detectable CD4 T cell responses to Env or accessory
proteins being detected. This is in contrast to the ﬁndings of studies in individuals with
chronic clade B infection, which have detected CD4 T cell responses targeting
multiple epitopes within Env gp120 and rarely targeting overlapping peptide (OLP) 25
in Gag (19), suggesting that the immunodominance hierarchy of HIV-speciﬁc CD4 T
cell targeting may be inﬂuenced by the infecting clade (20). Moreover, our study has
identiﬁed 22 peptides that have not been described to be immunodominant epitopes
in previous studies of HIV-1 clade C.
As the cohort was stratiﬁed into controllers and progressors, we next evaluated
whether HIV-speciﬁc CD4 T cell responses within these two groups may be directed
at different epitopes. However, there was no signiﬁcant difference between the two
groups (P  0.65) (Fig. 1B). A few epitopes were exclusively targeted by each group at
low frequencies of 3%. There were particular epitopes that, albeit they were targeted
by both groups, were more targeted by progressors, such as Gag25, which was targeted
by only 3% of controllers and 13% of progressors (Fischer’s exact test, P  0.01).
Notably, the highly immunodominant Gag41 epitope was targeted by both controllers
FIG 1 (A) Frequency of targeting of HIV-speciﬁc CD4 T cell responses to overlapping peptides across the
HIV-1 proteome. HIV-speciﬁc CD4 T cell responses against a panel of 410 OLPs spanning the entire HIV
proteome were screened. The labels on the x axis indicate the start of the relevant HIV protein or
subprotein. The percentages of responders (30/72 individuals screened) with epitope-speciﬁc CD4 T cell
responses are shown. (B) Percentages of epitope-speciﬁc CD4 T cell responses targeting the respective
OLPs across the Gag and Nef proteins between controllers (n  13) and progressors (n  17) from a
chronically infected cohort. No signiﬁcant differences were observed between the two groups (P  0.65,
based on a nonparametric two-tailed t test). Further analysis of each individual response indicated a
signiﬁcant (*, P  0.01, Fisher’s exact test) more predominant targeting of Gag25 in the Gag p24 region by
progressors than by controllers.
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and progressors (23% and 17% responders, respectively), thus providing sufﬁcient
coverage of both groups for in-depth quantitative and qualitative evaluation of the
Gag41-speciﬁc CD4 T cell responses by MHC class II tetramers and the relationship of
these responses to the viral load.
HLA-DRB1*13:01 and HLA-DRB1*11:01 are the most frequent alleles among
CD4 T cell responders. Having identiﬁed immunodominant epitopes targeted in
chronic clade C infection, we next performed HLA class II typing as described in the
Materials and Methods to determine the HLA class II allele frequencies among the
subjects with detectable responses by the IFN- ELISPOT assay (n  30) (Fig. 2A). Our
data suggest that individuals with the strongest HIV-speciﬁc CD4 T cell responses
possessed the class II HLA-DRB1*13:01 allele (n 12, 21% of responders). The next most
common alleles were DRB1*11:01 and DRB1*03:02, expressed by 14% and 9% of
responders, respectively. Interestingly, the most common DRB1 alleles among the
responders in our study were also the most frequent in the larger cohort with chronic
clade C infection (n  439), whereby DRB1*03:02 was the most common allele
observed (n 146, 33%), followed by DRB1*11:01 (n 111, 25%) and DRB1*13:01 (n
102, 23%) (16). It is important to note that DRB1*13 alleles have been reported to confer
a protective effect (13), with DRB1*13:03 in particular having been shown to mediate
protection independently of ethnicity, sex, and viral clade (16).
HLA-DRB1 allele restriction characteristics of HIV-speciﬁc CD4 T cell re-
sponses in clade C infection. Having deﬁned the frequencies of these class II alleles
in this cohort with chronic clade C infection, we next identiﬁed DRB1 restricting alleles
using the HLA restriction assay previously described by Ranasinghe et al. (12). We
observed high levels of peptide promiscuity, which is known to be a distinctive feature
of antigen-speciﬁc CD4 T cell recognition (21), with the presentation of a single
TABLE 1 Immunodominant peptides targeted by study participantsa
Peptide Protein
Location in HXB2
(amino acids) OLP sequence
% of responders
targeting OLPb
41 p24 164–181 YVDRFFKTLRAEQATQDV 40
40 p24 156–173 GPKEPFRDYVDRFFKTLR 23
6 p17 37–51 ASRELERFALNPGLL 20
25 p24 46–62 GATPQDLNTMLNTVGGH 20
37 p24 133–150 WIILGLNKIVRMYSPVSI 20
62 p15 85–102 FLQSRPEPTAPPAESFRF 17
22 p24 23–40 WVKVIEEKAFSPEVIPMF 13
81 Nef 104–121 KKRQEILDLWVYHTQGYF 13
2 p17 9–26 RGGKLDKWEKIRLRPGGK 10
5 p17 32–46 KHLVWASRELERFAL 10
35 p24 117–134 WMTSNPPVPVGDIYKRWI 10
46 p24 200–217 TILRALGPGASLEEMMTA 10
60 p15 72–89 GKIWPSHKGRPGNFLQSR 10
168 RT 15–32 GMDGPKVKQWPLTEEKIK 10
4 p17 25–41 GKKHYMLKHLVWASREL 7
7 p17 42–58 ERFALNPGLLETSEGCK 7
11 p17 70–86 TGTEELRSLYNTVATLY 7
14 p17 92–110 IEVRDTKEALDKIEEEQNK 7
34 p24 109–126 STLQEQIAWMTSNPPVPV 7
57 p15 51–68 WKCGKEGHQMKDCTERQA 7
58 p15 59–75 QMKDCTERQANFLGKIW 7
64 p15 103–123 RFEETTPAPKQEPKDREPL 7
79 Nef 88–105 SFFLKEKGGLEGLIYSKK 7
104 Rev 72–88 PLQLPPIERLHIDCSES 7
148 Protease 22–40 RANSPTSRELQVRGDNPR 7
289 gp120 1–7 MRVMGIQRNCQQWWRW 7
290 gp120 7–27 QRNCQQWWRWGILGFWML 7
336 gp120 351–371 EHFPNKTIKFAPSSGGDLEI 7
aImmunodominance hierarchy of frequently targeted HIV-speciﬁc CD4 T cell responses in the cohort with
chronic clade C HIV infection.
bPercentages were calculated according to the results for those individuals that demonstrated an HIV-speciﬁc
CD4 T cell response.
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peptide on numerous HLA class II variants. Gag41 in the Gag p24 region, previously
identiﬁed to be the epitope most frequently targeted by HIV-speciﬁc CD4 T cells in
clade B (17, 19) and also shown to be the most frequently targeted epitope in this
cohort, exhibited the highest levels of promiscuity, being restricted by 7 different
HLA-DRB1 variants (Fig. 2B). The promiscuity in peptide binding is likely mediated by
the open conformation of HLA class II, which allows long peptides recognized by
CD4 T cells to extend beyond the HLA binding groove (12). Despite the high
degree of HLA-DRB1 binding promiscuity, marked differences in the number of
peptides that were restricted by each DRB1 variant were observed. Variants such as
DRB1*14:01 and DRB1*04:01 had no detectable contribution to overall peptide
restrictions, whereas DRB1*13:01 and DRB1*11:01 restricted 9 and 4 HIV-speciﬁc
peptides, respectively.
Use of HLA class II tetramers for sensitive detection of HIV-speciﬁc CD4 T
cells. Having identiﬁed immunodominant CD4 T cell epitopes and the most common
restricting HLA DRB1 allele variants in a large number of clade C responders (30/72
individuals tested), the information was used to successfully generate and validate
the following tetramers: DRB1*03:01 (Gag37), DRB1*11:01 (Gag41), and DRB1*13:01
FIG 2 HLA class II restriction characteristics of HIV-speciﬁc CD4 T cell responses in a cohort with chronic
clade C infection. (A) Frequency of various HLA-DRB1 allele variants in CD4 T cell responders (n 30). The
number of responders possessing each allele is indicated in parentheses above each bar. (B) HLA-DRB1
allele restriction characteristics of HIV-speciﬁc CD4 T cell responses in individuals with clade C infection
(promiscuous epitopes). The restricting HLA alleles for each overlapping peptide are indicated above each
bar. Alleles that are highlighted in red were used to generate MHC class II tetramers.
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(Gag37 and Gag41). Each of these was conjugated to both phycoerythrin (PE) and
allophycocyanin (APC) (Table 2). The newly synthesized tetramers were then used
to evaluate the role of HIV-speciﬁc CD4 T cell responses in the pathogenesis of
clade C HIV-1 infection. To our knowledge, these particular MHC class II tetramers
have not been synthesized before in the setting of clade C infection. Furthermore,
our study is the ﬁrst to generate and utilize the DRB1*11:01 tetramer to Gag41 to
study CD4 T cell responses.
Given the low frequency of HIV-speciﬁc CD4 T cell responses (22), a dual PE and
APC tetramer-staining strategy with gating on double-staining cells was used to
increase our ability to detect genuine tetramer-positive (tetramer) cells and minimize
nonspeciﬁc background staining (Fig. 3A). Class II tetramer staining on CD8 T cells was
also assessed for each sample to ensure that there was minimal nonspeciﬁc tetramer
binding (Fig. 3A). The speciﬁcity was conﬁrmed by staining 3 HIV-negative samples,
TABLE 2MHC class II tetramersa used for analysis of tetramer CD4 T cells
HIV tetramer Sequence OLP Clade
HLA-DRB1*03:01 WIILGLNKIVRMYSPVI Gag37 C
HLA-DRB1*11:01 YVDRFFKTLRAEQATQDV Gag41 C
HLA-DRB1*13:01 WIILGLNKIVRMYSPVI Gag37 C
HLA-DRB1*13:01 YVDRFFKTLRAEQATQDV Gag41 C
aMHC class II tetramers were produced according to allele variants associated with the most frequently
targeted peptides and the highest number of responders.
FIG 3 Frequency of tetramer-positive CD4 T cells in chronically infected controllers and progressors and
HIV-negative subjects. (A, B) Representative ﬂow plots indicating a dual PE and APC tetramer-staining
strategy with gating on double-stained cells, which was used to increase the ability to detect genuine
tetramer cells and minimize nonspeciﬁc background staining on CD8 T cells, from an HIV-infected
individual (A) and from an HIV-negative individual (B). (C, D) Differences in the percentage of CD4
tetramer T cells between controllers (Cont) and progressors (Prog) for all class II DRB1*03:01,
DRB1*11:01, and DRB1*13:01 tetramers utilized (P  0.0001) (C) and for only the DRB1*11:01
tetramer (P  0.0005) (D).
MHC Class II Tetramers and CD4 T Cell Responses Journal of Virology
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none of which stained positive (representative data are shown in Fig. 3B). Low-
frequency class II DRB1*03:01, DRB1*11:01, and DRB1*13:01 tetramer binding CD4 T
cells were readily detectable in 11 controllers expressing the requisite DRB1 alleles at
a median frequency of 0.31% (interquartile range [IQR], 0.045% to 0.41%) of the total
CD4 T cells. Notably, the median frequency of class II tetramer binding cells in 10
chronic progressors expressing the requisite DRB1 was 0.036% (IQR, 0.015% to
0.27%; P  0.0001), which was 10-fold lower than that in controllers (Fig. 3C).
Analysis of the DRB1*11-Gag41 tetramer binding responses also showed a higher
frequency in controllers than progressors (P  0.0005) (Fig. 3D). The controllers and
progressors were matched for expression of DRB1*11, with an equal number of
each expressing this allele. These data suggest that HIV-speciﬁc CD4 T cell
responses targeting immunodominant Gag41 in the context of DRB1*11 expression
are associated with the maintenance of low levels of viremia during chronic clade
C HIV infection.
Dominance of monospeciﬁc HIV-speciﬁc CD4 T cell responses in controllers
and progressors. Given that tetramers can bind antigen-speciﬁc cells irrespective of
function, we next examined the range of CD4 T cell functionalities that constitute
tetramer responses. Peripheral blood mononuclear cells (PBMCs) were stimulated
with an HIV clade C Gag pool or the Gag41 or Gag37 OLP. Multicolor ﬂow cytometry
was used to detect and enumerate key effector CD4 T cell functions in individuals with
tetramer responses. We measured markers that deﬁne key CD4 T cell functional
subsets. Our analysis included the degranulation marker CD107a, which was used to
enumerate cytolytic CD4 T cells (7); IFN- and interleukin-2 (IL-2), which were used to
identify Th-1 helper cells (23); and IL-21, which was included to identify cells that
augment B cell and CD8 T cell effector functions (9, 24). To investigate if any of the
measured functions impact virus suppression, we compared the expression level of
each marker in controllers and progressors. The HIV controllers exhibited higher
mean/median levels of expression of each of the four functions than the progressors in
response to stimulation with a mix of Gag peptides (Fig. 4A and B), in response to the
immunodominant Gag41 (Fig. 4C), or in response to staphylococcal enterotoxin B (SEB)
(Fig. 4D), yet only the response to SEB reached statistical signiﬁcance after correc-
tion for multiple comparisons. Previous studies have shown that the ability to
simultaneously elaborate multiple functions is associated with protective immunity
against several viral infections (reviewed by Harari et al. [25]); moreover, multifunc-
tional CD4 T cell responses were associated with protection in the RV144 trial
(26–28). Therefore, we next examined if certain combinations of functions were
associated with slow HIV disease progression. Combinatorial polyfunctionality anal-
ysis showed a preponderance of monospeciﬁc responses for both controllers and
progressors (Fig. 4E and F). The high frequency of monofunctional cells highlights
the limitation of assays which rely on a single function as a surrogate for the entire
HIV-speciﬁc CD4 T cell response.
Gag-speciﬁc tetramer CD4 T cell responses inversely correlated with the HIV
viral load. Given the observed link between CD4 T cell responses and the mainte-
nance of low levels of viremia, we next interrogated whether maintenance of Gag-
speciﬁc (tetramer) CD4 T cell responses during chronic HIV infection inﬂuences
disease progression. The frequency of Gag-speciﬁc CD4 T cells measured by four MHC
class II tetramers negatively correlated with the contemporaneous viral load (Spearman
r  0.5, P  0.005) when the data for both controllers and progressors were analyzed
together (Fig. 5A). However, in separate analyses of the responses of controllers
(Spearman r  0.3, P  0.3) and progressors (Spearman r  0.01, P  0.9), the
correlation did not reach statistical signiﬁcance, which may have been due to the small
sample size. Furthermore, a negative correlation between the frequency of tetramer
CD4 T cells targeting DRB1*11-Gag41 and the contemporaneous viral load (Spearman
r  0.5, P  0.02) was also observed (Fig. 5B). Interestingly, the levels of IFN-
secretion measured by ICS exhibited a similar negative correlation with the viral load
(Spearman r0.7, P 0.003) (Fig. 5C). However, the levels of IL-2, IL-21, and CD107a
Laher et al. Journal of Virology
April 2017 Volume 91 Issue 7 e02477-16 jvi.asm.org 8
 o
n
 D
ecem
ber 28, 2017 by KB, Københavns Universitetsbibliotek
http://jvi.asm.org/
D
ow
nloaded from
 
secretion did not correlate with the contemporaneous viral load (data not shown). This
observation prompted us to examine the relationship between tetramer CD4 T cells
and cytokine-positive (cytokine) cells following stimulation with Gag peptides. Inter-
estingly, only IFN--secreting cells correlated with tetramer cells (Spearman r  0.7,
P  0.001) (Fig. 5D). There was no correlation between the level of IL-2 or IL-21
secretion and the frequency of tetramer responses (Fig. 5E and F), and the correlation
between the level of secretion of the degranulation marker CD107a and the frequency
of tetramer responses was only of borderline signiﬁcance (P  0.04) (Fig. 5G). The
plausible explanation for the lack of a positive correlation between tetramer cells
and these cytokine cells may be that some IL-2- and IL-21-secreting cells recog-
nized different epitopes within Gag or, alternatively, were restricted by other class
II alleles.
Overall, these data highlight the heterogeneity of the effector functions of HIV-
speciﬁc CD4 T cells and illustrate the advantage of using tetramers to identify
FIG 4 HIV-speciﬁc CD4 T cell polyfunctional responses. (A) Graphical representation of intracellular cytokine staining of
controller and progressor individuals on the basis of CD107a stimulation. (B to D) The expression of CD107a, IFN-, IL-2, and
IL-21 in 14 chronically infected subjects divided into controllers and progressors in response to Gag pool stimulation (stim) (B),
to Gag41 stimulation (C), and to SEB stimulation (D) was measured. (E, F) The bars depict the frequency of CD4 T cells
expressing a combination of the functions indicated below the x axis.
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antigen-speciﬁc cells without relying on function. Furthermore, these data suggest that
immunodominant Gag-speciﬁc CD4 T cell responses are linked with better control of
HIV, indicating that these responses may play a role in suppressing HIV replication by
antiviral effector functions.
Ex vivo-expanded HIV-speciﬁc CD4 T cells from controllers display increased
cytolytic activity. The low-frequency HIV-speciﬁc CD4 T cells detected by class II
tetramers may mostly be cells with low-frequency memory responses, which have a low
FIG 5 Gag-speciﬁc tetramer CD4 T cell responses correlate with markers of HIV disease progression. (A) The frequency of HIV-speciﬁc CD4
T cells measured by four class II tetramers negatively correlated with the contemporaneous viral load (VL) (Spearman r  0.5, P  0.005). (B)
A negative correlation between the most dominant Gag41 response (DRB1*11:01) and the contemporaneous viral load was also observed. (C)
IFN- secretion, measured by ICS, exhibited a similar negative correlation with the viral load (Spearman r  0.7, P  0.003). (D to G) In addition,
the relationship between tetramer CD4 T cells and cytokine cells following stimulation with HIV peptides was analyzed.
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potential to secrete cytokines ex vivo. Moreover, several studies of HIV-speciﬁc CD8 T
cell responses have demonstrated that ex vivo expansion is needed to accurately
measure the cytolytic potential of memory responses (29, 30). We reasoned that this
might also be true for HIV-speciﬁc CD4 T cell responses. Thus, we next performed a
stimulated expansion of the low-frequency HIV-speciﬁc CD4 T cells that were detected
by tetramers and evaluated the cytolytic potential of these expanded cells. Cultured
stimulation of HIV-speciﬁc CD4 T cells from controllers resulted in the signiﬁcant
expansion of the tetramer populations compared to the levels at the baseline (P 
0.03) (Fig. 6A and B), whereas class II tetramer populations from progressors expanded
FIG 6 Frequency of tetramer-positive CD4 T cells in chronically infected controller and progressor individuals following cell
expansion. (A, C) Representative ﬂow plots indicating a dual PE and APC tetramer-staining strategy with gating on double-
stained cells at the baseline and 2 weeks following expansion of peptide-speciﬁc T cell lines from an HIV controller (A) and from
an HIV progressor (C). (B, D) Differences in the percentage of CD4 tetramer T cells in 3 controllers, indicating the responses
at the baseline and 2 weeks after expansion in culture (red) for all class II DRB1*03:01, DRB1*11:01, and DRB1*13:01 tetramers
utilized (P 0.02) (B), and for 3 progressors, using the same principle (D). (E) Representative ﬂow plots indicating the functional
responses by IFN--speciﬁc CD4 T cells to granzyme A, granzyme B, and CD107a following 2 weeks of expansion. (F)
Comparison of IFN--speciﬁc CD4 T cells to granzyme A (P  0.03), granzyme B (P  0.01), and CD107a (P  0.9) between
controllers and progressors.
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poorly (P 0.2) (Fig. 6C and D). Assessment of the cytolytic activity of ex vivo-expanded
HIV-speciﬁc CD4 T cells by intracellular cytokine staining (Fig. 6E) showed that
controllers had a signiﬁcantly higher proportion of HIV-speciﬁc cells expressing gran-
zyme A (P  0.03) and granzyme B (P  0.01) than progressors (Fig. 6F). No signiﬁcant
differences for CD107a were observed between the groups. Taken together, these data
suggest that HIV-speciﬁc CD4 T cells from controllers have higher proliferative and
cytolytic functions than those from progressors, suggesting their potential contribution
to direct antiviral activity during chronic HIV infection.
DISCUSSION
Together, the data presented here demonstrate an association between the fre-
quency of HIV-speciﬁc CD4 T cell responses targeting distinct immunodominant
epitopes in Gag and immune control of clade C HIV viremia. In particular, we show that
CD4 T cells targeting Gag41 in the context of HLA-DRB1*11 are associated with
immune control of HIV (in HLA-matched individuals). To our knowledge, this is the ﬁrst
study to demonstrate that CD4 T cells directed against a single peptide-HLA class II
speciﬁcity are associated with low levels of HIV viremia. Indeed, although CD8 T cell
targeting of HLA class I-peptide complexes, such as B*27-KK10, is well-known to be
associated with the spontaneous control of HIV infection (31, 32), previous studies
assessing the contribution of HIV-speciﬁc CD4 T cells to HIV immune control have
either focused on the expression of distinct HLA-DRB1 alleles (12–14, 16) or identiﬁed
particular CD4 T cell epitopes, such as Gag41, targeted at different stages of disease
(17, 19, 20, 33). The ﬁnding that there is an association between the frequency of
HIV-speciﬁc CD4 T cells targeting the DRB1*11-Gag41 complex and low levels of HIV
viremia (in our assessment of 20 HIV-positive HLA-matched individuals) is consistent
with our hypothesis that the maintenance of robust HIV-speciﬁc CD4 T cell responses
to the Gag p24 region may contribute to the immune control of chronic HIV replication
rather than to the fueling of disease progression through infection of activated HIV-
speciﬁc CD4 targets.
It is important to note that although the frequency of HIV-speciﬁc CD4 T cells
measured by four MHC class II tetramers negatively correlated with the contempora-
neous viral load when the data for controllers and progressor were analyzed together,
the correlation did not reach statistical signiﬁcance when the data for each group were
analyzed separately. This may have been due to the smaller sample size when the data
for each group were analyzed separately. Nevertheless, the fact that controllers main-
tained higher frequencies of class II tetramer CD4 T cells than progressors suggests an
association between higher frequencies of virus-speciﬁc CD4 T cell responses and the
maintenance of lower viral loads.
Although our analysis of peptide-stimulated HIV-speciﬁc CD4 T cells found that
they predominantly secreted IFN- directly ex vivo, we speculate that in vivo these
epitope-speciﬁc CD4 T cells may provide superior helper activity to HIV-speciﬁc CD8
T cells that enhances the suppression of HIV replication through a cocktail of cytokine
signals or they may directly kill HIV-infected CD4 T cell and macrophage targets.
Indeed, the ﬁnding that our ex vivo-expanded CD4 T cell lines expressed granzymes
A and B, the expression of which was signiﬁcantly enhanced in HIV controllers, supports
the hypothesis that CD4 T cells targeting immunodominant Gag peptides may exhibit
functions that contribute to the immune control of HIV (7, 34). However, since it is not
possible to determine cause versus consequence in our cross-sectional analysis, it
remains unclear whether weak HIV-speciﬁc T cell responses are a result of ongoing viral
replication or, alternatively, whether the superior frequency and superior function of
these responses contribute to effective immune control of the virus or some T cell
speciﬁcities may simply be better preserved in individuals with low levels of viremia
and low levels of immune activation.
The improved elucidation of HIV-speciﬁc CD4 T cell responses and an enhanced
understanding of how such CD4 T cells may promote the generation of protective
CD8 T cell and B cell responses or mediate a direct antiviral role are highly relevant
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for future HIV vaccine design. Currently, the development of assays that can fully
quantify all the relevant epitope-speciﬁc responses remains a major challenge in
natural infection and vaccine studies because of the tremendous complexity of CD4
T cell biology. This study employed MHC class II tetrameric complexes to enumerate
and characterize Gag p24-speciﬁc CD4 T cell populations ex vivo in HIV-infected
individuals bearing HLA DRB1*11:01, DRB1*13:01, and DRB1*03:01 alleles. Overall, our
study shows that MHC class II tetramers are very sensitive for detecting directly ex vivo
HIV-speciﬁc CD4 T cells present at very low frequencies. Our approach provides an
alternative method of identifying antigen-speciﬁc CD4 T cells without relying on
function and removes the bias associated with the in vitro stimulation required for
functional assays and the limitation associated with the detection of only subsets of
cells capable of secreting cytokines. A notable limitation of our study, however, is the
lack of availability of a wide range of class II tetramers complexed with other MHC class
II DRB1 alleles or the less well characterized DP and DQ alleles. Notwithstanding this
limitation, the screening data from the ELISPOT assay show that we were able to
measure most of the immunodominant responses which were restricted by DRB1
alleles pertinent to this African population for which we successfully generated a subset
of relevant class II tetramers. Taken together, these data demonstrate that HIV-speciﬁc
CD4 T cell responses restricted to DRB1*11-Gag41 are associated with immune control
of HIV-1 infection and highlight the advantages of class II tetramer technology in
evaluating HIV-speciﬁc CD4 T cell responses in future natural infection and vaccine
studies.
MATERIALS AND METHODS
Cohort characteristics. A total of 80 subjects chronically infected with HIV-1 clade C (76.3% female
[n 61] and 23.8% male [n 19] subjects; the percentages do not total 100% because of rounding) from
the local Zulu/Xhosa population, recruited as part of the Sinikithemba cohort (35) in Durban, South
Africa, were studied. The Biomedical Research Ethics (BREC) of the University of KwaZulu-Natal and the
institutional review board (IRB) of Massachusetts General Hospital approved this study. All study
participants were antiretroviral naive at the time of enrollment. Sociodemographic characteristics,
plasma viral load measurements, and CD4 T cell counts were obtained at the baseline. Follow-up CD4
T cell counts and plasma viral load measurements were performed at 3 months and 6 months. The
individuals recruited for this study were stratiﬁed into two major groups: 34 HIV controllers, deﬁned here
as individuals who maintained lower viral loads of 2,000 HIV RNA copies/ml for 1 year, and 46 HIV
chronic progressors, deﬁned here as individuals who maintained viral loads of 2,000 HIV RNA copies/
ml, on the basis of the contemporaneous viral load (Table 3). HLA-DRB1 typing was performed for all
participants as described previously (16). Cryopreserved peripheral blood mononuclear cell (PBMC)
samples from each individual were utilized for all assays. An initial number of 72 participants were
screened for HIV-speciﬁc CD4 T cell responses using the ELISPOT assay. Individuals that made a CD4
response were then screened using the HLA restriction assay to determine the restricting alleles and
epitopes. For additional comparisons of controllers and progressors, data for an additional 8 individuals
that were not utilized in the initial screening were added to the data set. Hence, the total number of
participants in the study was 80 (Table 3). MHC class II tetramers were synthesized and tested for
approximately one-quarter (21/80) of study subjects in this cohort with clade C infection who expressed
the matching HLA class II DRB1 alleles.
CD8 T cell depletion and modiﬁed IFN- ELISPOT assay. A modiﬁed IFN- ELISPOT assay was
used to screen all chronically infected subjects. Cryopreserved PBMCs were thawed, and CD8 T cells
TABLE 3 Summary of clinical characteristics of study participantsa
Stratum deﬁnition (viral load)
No. of
subjects
Median (range) viral
load (copies/ml)
Median (range)
CD4 count
(cells/l)
No. of subjects tested by:
Screening (ELISPOT
assay  HLA
restriction)
Tetramer
staining
Intracellular
cytokine
staining
Controllers (50–2,000 copies/ml) 34 400 (20–2,000) 684.5 (340–1,162) 30 11 6
Progressors (2,001– 50,000 copies/ml) 46 26,800 (2,100–4,540,000) 415.5 (225,934) 42 10 8
Total 80 72 21 14
aPatient demographics were as follows: by sex, 76.3% were female (n  61) and 23.8% were male (n  19), and by race, 97.5% were African and 1.2% each were
Asian and Caucasian (percentages do not total 100% because of rounding). All study participants included in the tetramer and intracellular cytokine staining studies
maintained viral control for a minimum of 1 year, including at the time point of analysis in the case of controllers, and had comparable CD4 cell counts (P  0.87).
Individuals utilized for the initial screening and HLA restriction assays were not necessarily the same individuals used to perform tetramer and intracellular cytokine
staining.
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were depleted using Miltenyi magnetically activated cell sorting CD8 microbeads (Miltenyi Biotech,
Bergisch Gladbach, Germany). The initial screening was carried out using a megamatrix approach (36, 37)
with consensus clade C HIV-1 peptides custom produced at the Massachusetts General Hospital Core
facility. The megamatrix involved the use of 410 18-mer overlapping peptides (OLPs), which overlapped
by 10 amino acids, that spanned the entire HIV-1 proteome. These were arranged into 72 pools of
between 10 and 12 peptides in each pool, such that an individual peptide was uniquely represented in
two different pools. Each megamatrix peptide pool was cocultured with 100,000 CD8-depleted cells per
well in 96-well polyvinylidene plates (catalog number MAIP S45; Millipore, MA, USA) that had been
precoated with 100 l the MAb1-D1k anti-IFN- monoclonal antibody (MAb; 0.5 g/ml; Mabtech,
Stockholm, Sweden) overnight at 4°C. Positive responses from the initial megamatrix screening were
conﬁrmed using a separate ELISPOT assay at the single-peptide level. For screening at the single-peptide
level, a total of 100,000 CD8-depleted PBMCs per well were plated in 96-well polyvinylidene plates
(catalog number MAIP S45; Millipore, MA, USA) that had been precoated with 100 l the MAb1-D1k
anti-IFN- monoclonal antibody (0.5 g/ml; Mabtech, Stockholm, Sweden) overnight at 4°C in the
presence or absence of speciﬁc HIV-1-derived OLPs in a ﬁnal volume of 200 l R10 medium (RPMI 1640
containing 10% heat-inactivated fetal calf serum [FCS], 2 mM L-glutamine, 50 U/ml of penicillin, 50 g of
streptomycin/ml, and 10 mM HEPES). Each well contained a single OLP (10 l) at a ﬁnal concentration
of 2 g/ml for each individual peptide. Cells in medium without antigenic stimuli represented negative
controls. Phytohemagglutinin (PHA) antigen (Sigma-Aldrich, St. Louis, MO, USA), which served as a
positive control for both cell viability and the functionality of the immunoassay, was added at a
concentration of 5 g/ml. The plates were incubated for 40 h at 37°C in 5% CO2 to elicit the maximum
amount of cytokine secretion. The ELISPOT assay plates were then processed as previously described
(19). An antigen-speciﬁc CD4 T cell response was considered positive only if the level of the response
was at least 3 times the mean background level and also if the standard deviation of the number of
spot-forming cells (SFC) was 3 times the standard deviation of the number of SFC for the negative
controls. The breadth of the responses was deﬁned as the sum of the IFN--positive peptide responses
within a given individual across the entire HIV proteome or within a speciﬁed protein. Positive responses
to two adjacent overlapping peptides were relatively rare in our cohort (2/30 responders), but where they
occurred, the two overlapping peptides were treated as a single epitope to ensure that the breadth of
CD4 T cell responses was not overestimated.
HLA genotyping. High-resolution (4-digit-allele) class I/II genotyping was carried out using standard
sequence-based typing protocols (16). In brief, HLA class I genes were ampliﬁed by PCR with primers
spanning exons 2 and 3, and HLA class II typing was based on exon 2. Sequencing results were
interpreted using ASSIGN (version 3.5) software, developed by Conexio Genomics (Fremantle, Western
Australia, Australia).
HIV-speciﬁc CD4 T cell lines and HLA-DR restriction assay. A modiﬁed HLA-DRB1 restriction
assay was utilized as previously described (12) to deﬁne restricting HLA class II alleles. In brief, frozen
CD8-depleted PBMC samples from subjects with known CD4 T cell responses were used to generate
CD4 T cell lines. CD8-depleted PBMCs at a concentration of 2 million cells on a 24-well plate in R10
medium were stimulated with 10 g/ml of peptide. The cells were incubated at 37°C in 5% CO2. After
2 days, the cells were washed and fresh R10 medium supplemented with 100 U/ml recombinant IL-2 was
added. The CD4 T cell lines were fed twice weekly with regular medium replenishment. After 14 days,
the T cell lines were simultaneously assessed for their speciﬁcity and HLA-DR restriction using a large
panel of L cell lines (LCLs), which are mouse ﬁbroblasts, each stably transfected with a single recombinant
human HLA-DR molecule, as previously described (21). Each LCL was pulsed with 10 g/ml peptide for
90 min at 37°C in 5% CO2 and washed ﬁve times to remove free peptide. Overlapping peptides from the
HIV-1 clade C consensus sequence were used in the assay. Ten thousand peptide-pulsed LCLs were
cocultured in triplicate with 50,000 cells of each respective CD4 T cell line per well on a precoated IFN-
plate. As a negative control, each CD4 T cell line was cocultured in triplicate with the appropriate LCL
in the absence of peptide. As a positive control, PHA was added at 2 g/ml. The plates were incubated
for 18 h at 37°C in 5% CO2 and processed by the usual ELISPOT assay protocol described above. An Aid
ELISPOT assay reader (Autoimmun Diagnostika, Germany) was used to determine the number of SFC per
50,000 cells of the CD4 T cell line. HLA-DR restriction was considered positive if the level was at least3
times the mean background level and also 3 times the standard deviation for the negative-control
wells.
MHC class II tetramers. The HIV clade C p24 Gag41 peptide (YVDRFFKTLRAEQATQDV) was complexed
to recombinant human DRB1*11:01 or DRB1*13:01. In addition, the HIV clade C p24 Gag37 peptide (WIILG
LNKIVRMYSPVSI) was complexed to recombinant human DRB1*13:01 and DRB1*03:01. These tetramers are
referred to as the speciﬁc HLA together with the peptide designation here (e.g., DRB1*11:01-Gag41). All
tetramers were conjugated to PE and APC at a concentration of either 454 nM or 432 nM. The tetramers were
produced in the laboratory of Søren Buus under previously described conditions (38).
Tetramer and surface staining. Unless stated otherwise, PBMCs were incubated with MHC class II
tetramers with a ﬁnal staining concentration of 30 nM for 1 h at 37°C in medium. After the cells were
washed with cold 2% FCS–phosphate-buffered saline (PBS) buffer, antibodies to cell surface molecules
were added and the mixture was incubated at 4°C for 30 min. The following anti-human-conjugated
antibodies were used: CD3-BV785-OKT3 (catalog no. 317330; BioLegend, San Diego, CA, USA), CD4-
AF700-RPA-T4 (catalog no. 557922; BD, San Jose, CA, USA), and CD8-BV605-SK1 (catalog no. 564116; BD).
PBMCs were also stained with LIVE/DEAD ﬁxable aqua cell viability dye (catalog no. L34957; Invitrogen).
Stained cells were washed with 2% FCS–PBS buffer and ﬁxed with ﬁxation medium A (catalog no.
GAS001S-100; Invitrogen). Data were acquired on an LSR Fortessa ﬂow cytometer (serial number
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H647794E6049; BD). Flow data were analyzed using FlowJo software (version 10.1; TreeStar Ashland,
OR, USA).
Intracellular cytokine staining. Brieﬂy, PBMCs were incubated overnight with a clade C consensus
Gag peptide pool or Gag41 as the speciﬁc antigen/stimulus and staphylococcal enterotoxin B (SEB)
(Sigma) as a positive control in the presence of a Golgi apparatus stop protein transport inhibitor (BD
Biosciences) and Golgi apparatus plug protein transport inhibitor (BD Biosciences), according to the
manufacturer’s instructions. Anti-CD107a-PE-Cy5-H4A3 (catalog no. 555802; BD) was also added at the
beginning of the stimulation period. After the stimulation, intracellular cytokine staining was performed
according to the BD Biosciences ICS protocol. Unstimulated cells were used as a control. Cells were
stained with LIVE/DEAD ﬁxable aqua dead cell viability dye (catalog no. L34957; Invitrogen) and
ﬂuorescent antibodies against CD3-BV711-OKT3 (catalog no. 317328; BioLegend), CD4-BV650-SK3 (cat-
alog no. 563875; BD), and CD8-AF700-RPA-T8 (catalog no. 557945; BD). Cells were permeabilized and
ﬁxed with BD intracellular staining reagents according to the manufacturer’s instructions (BD Biosci-
ences) and stained with cytokine-speciﬁc antibodies against IFN-–PE–Cy7–B27 (catalog no. 557643; BD),
IL-21–PE–3A3-N2.1 (catalog no. 560463; BD), and IL-2–ﬂuorescein isothiocyanate–5344.111 (catalog no.
340448; BD). Cells were acquired on an LSR Fortessa ﬂow cytometer (serial number H647794E6049; BD).
Flow data were analyzed using FlowJo software (version 10.1; TreeStar).
Ex vivo expansion of HIV-speciﬁc CD4 T cells. MHC class II tetramer staining was performed prior
to culture. Cells were then cultured at 37°C in 5% CO2 for 14 days in the presence of HIV clade C p24
Gag37 and 41 OLPs, as described above for the HIV-speciﬁc CD4 T cell lines. On day 14, the cells were
washed three times with fresh R10 medium and rested at 37°C in 5% CO2 overnight in fresh R10 medium.
On the following day, MHC class II tetramer staining was performed to determine the levels of expansion.
The cells were then stimulated for 6 h with the same peptides used for expansion, and the cytolytic
activity of the expanded cells was assessed by ICS staining for granzyme A-AF488-CB9 (catalog no.
507212; BioLegend), granzyme B-AF700-GB11 (catalog no. 560213; BD), and CD107a-PE-Cy5-H4A3 (cat-
alog no. 555802; BD).
Statistical analysis. Statistical analysis and graphical presentation were performed using GraphPad
Prism (version 5.0) software (GraphPad Software Inc., La Jolla, CA, USA). Spearman’s rank correlation was
used to assess the relationship between the immune responses and the viral load. Statistical analysis of
signiﬁcance was calculated using the Kruskal-Wallis test with Dunn’s post hoc analyses for multiple
comparisons. The signiﬁcance of the nonrandom associations (contingency) between controllers and
progressors was computed using Fisher’s exact test. In addition, the Mann-Whitney U test was
utilized to compare differences between two groups. Statistical signiﬁcance was set at a P value
of 0.05.
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